Bristol Myers Squibb (BMY) Receivables - Net (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Receivables - Net data on file, last reported at $9.4 billion in Q1 2026.

• Receivables - Net for Q1 2026 came in at $9.4 billion, down 13.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.4 billion (down 13.27% YoY), and the FY2025 annual result was $11.4 billion, up 6.21% from the prior year.
• Receivables - Net eased to $9.4 billion in Q1 2026 per BMY's latest filing, from $11.4 billion in the prior quarter.
• Over five years, Receivables - Net peaked at $11.4 billion in Q2 2024 and troughed at $8.5 billion in Q1 2022.
• A 5-year average of $10.4 billion and a median of $10.4 billion in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2023 and 2026: Receivables - Net rose 18.13% in 2023, then dropped 13.27% in 2026.
• A 5-year view of Receivables - Net shows it stood at $9.9 billion in 2022, then rose by 10.47% to $10.9 billion in 2023, then slipped by 1.59% to $10.7 billion in 2024, then climbed by 6.21% to $11.4 billion in 2025, then slipped by 17.93% to $9.4 billion in 2026.
• Business Quant data shows BMY's Receivables - Net at $9.4 billion in Q1 2026, $11.4 billion in Q4 2025, and $11.4 billion in Q3 2025.